key: cord-0754606-lfb3nbrm
authors: Gregory, Jennifer; Huynh, Bichtram; Tayler, Brittany; Korgaonkar-Cherala, Chaitali; Garrison, Gina; Ata, Ashar; Sorum, Paul
title: High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial
date: 2021-03-23
journal: JAMA Netw Open
DOI: 10.1001/jamanetworkopen.2021.2713
sha: 8d00044e8f0bd960fb2a161c578b680a7f45ba91
doc_id: 754606
cord_uid: lfb3nbrm

IMPORTANCE: Acute bacterial sinusitis is common, but currently recommended antibiotic treatment provides minimal benefit. OBJECTIVE: To confirm the previous finding that high-dose amoxicillin plus clavulanate (with double the amount of amoxicillin) may be superior to standard-dose amoxicillin plus clavulanate in adults. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, comparative-effectiveness randomized clinical trial was conducted from February 26, 2018, through May 10, 2020, at the academic primary care internal medicine and pediatrics practice of Albany Medical Center, located in Cohoes, New York. Participants included adults aged 18 years or older who were prescribed amoxicillin plus clavulanate for acute bacterial sinusitis diagnosed in accordance with the Infectious Diseases Society of America guidelines. INTERVENTIONS: Amoxicillin 875 mg with clavulanate 125 mg plus either placebo (standard dose) or amoxicillin 875 mg (high dose) twice a day for 7 days. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was a global rating of “a lot better” or “no symptoms” at the end of 3 days of treatment using a Global Rating of Improvement scale, with outcomes ranging from 1 (a lot worse) to 6 (no symptoms). The primary adverse effect outcome was severe diarrhea at 3 or 10 days after the start of treatment. RESULTS: At an unplanned interim analysis prompted by COVID-19 restrictions, 157 of a projected 240 participants had been enrolled (mean age, 48.5 [range, 18.7-84.0] years; 117 women [74.5%]), with 79 randomized to the standard dose and 78 to the high dose; 9 and 12, respectively, withdrew or were lost to follow-up before the assessment of the primary outcome. At day 3, 31 of 70 participants (44.3%) in the standard-dose group reported a global rating of “a lot better” or “no symptoms,” as did 24 of 66 (36.4%) in the high-dose group, for a difference of −7.9% (95% CI, −24.4% to 8.5%; P = .35). The study was, therefore, stopped for futility. Diarrhea was common in both groups by day 3, with any diarrhea reported in 29 of 71 participants (40.8%) receiving the standard dose and 28 of 65 (43.1%) receiving the high dose and severe diarrhea reported in 5 of 71 (7.0%) and 5 of 65 (7.7%), respectively. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial suggest that adults treated for clinically diagnosed acute sinusitis did not appear to benefit from taking high-dose compared with standard-dose amoxicillin plus clavulanate. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03431337

trial, we confirmed our expectation that very few of our patients are colonized with 47 penicillin-resistant pneumococci. We will not need to repeat this part of the study. 48 If we confirm that supplementing standard, immediate-release amoxicillin-49 clavulanate 875/125 bid with standard, immediate-release amoxicillin 875 bid results in 50 as substantial a benefit as in the initial study, we will be able to provide patients with a 51 treatment that is clearly more efficacious than placebo and that is also quite inexpensive 52 and easily available. If we find that the increase in adverse effects caused by the 53 supplemental amoxicillin does not outweigh, in patients' judgments, the added benefits of 54 treatment, we may change the way acute bacterial sinusitis is treated. 55 56

Study or increase in nasal discharge following a typical viral URI that lasted 5-6 days 80 and was initially improving ("double-sickening").

2. Patients who participated in the initial study will be eligible. Having chronic or 82 recurrent sinus infections was, and will again be, an exclusion criterion, but it 83 would decrease external validity to exclude patients who occasionally get sinusitis 84 and might, therefore, have participated in the past 3 years. We are able to obtain 85 different looking antibiotic and placebo pills, so that we can include even patients 86 who knew or who think they knew which formulation they took in the first study. 87

We will, however, plan a secondary analysis of those who were and were not in 88 the initial study. 89

Exclusion 12. After the study has been completed, the data analyzed, and a study report 281 accepted for publication, we will mail to each participant a summary of the study 282 results and an indication of the dosage she or he took. We will then destroy the 283 patient registry with its identifying information. 284 285

Data Analyses 286

Sample size: 287

To have a power of 80% to find again an increase in the primary endpoint from 34% to 288 52% with an alpha of 0.05 %, we would need 230 patients (115 in each group). To find 289

an increase only to 50%, we would need 292 patients (146 in each group). Our aim is, 290 therefore, to enroll at least 240 and ideally 300 patients. We enrolled 315 patients in the 291 previous study during an equivalent time period. 292

Outcomes: 293

Using SPSS, we will calculate 294 1. Chi-square analyses of the differences between the two arms in percentages of 295 global ratings, adverse effects, balance between good and bad effects, willingness 296

to take the antibiotic again, use of nasal steroids, and correct guesses of the dose 297 (with alpha set at 0.05). 298

2. T-test analyses of the differences between the two arms in the changes of average 299 SNOT-16 item rating from baseline to the end of day 3 and to the end of day 10 300 and in the mean rating of balance between good and bad effects at day 10 (alpha

IDSA clinical practice guideline for 403 acute bacterial rhinosinusitis in children and adults

Antibiotics for clinically diagnosed acute rhinosinusitis in adults

Amoxicillin middle ear 409 fluid penetration and pharmacokinetics in children with acute otitis media. Pediatr 410

Effectiveness of amoxicillin/clavulanate potassium 412 in the treatment of acute bacterial sinusitis in children

High-dose versus standard-dose 415

amoxicillin/clavulanate for clinically-diagnosed acute bacterial sinusitis: a 416 randomized clinical trial

Intranasal steroids for acute sinusits

0.05) 3023. Subgroup analyses for 1) and 2) of those who did vs. did not participate in the 303 initial study. 304 4. Repeat analyses combining a) the participants in this study and b) the participants 305in Time Period 2 of the initial study. 306 307Human subjects 308Risks 3091. Adverse physical effects 310In the initial study the primary adverse effects were diarrhea and (in women) 311vaginal discharge or itching. In the second time period, comparing the antibiotic 312formulations used in the current study, the increases in these adverse effects 313 associated with a doubling of the 1. The enrolling physician, office nurse, or pharmacy student will place the patient's 352 label next to the study # in the study patient registry. The patient number will be 353 written on a study folder as well as on the enrollment form, the Consent form, and 354 the baseline SNOT-16 that will be placed in that study folder (along with the day 355 3 and 10 telephone forms, as well as the Drop-out form if needed). The study 356 patient registry and the files will be kept in a locked room. 357 2. Communication between team members of patient names and telephone numbers 358 will be either verbally or via Albany Med email (hence secure). 3593. The participants who chose to enter their answers to the day 3 and 10 360 questionnaires electronically will receive an email from the study team member 361 with directions on how to access the secure Qualtrex website with their study 362 number and will enter their data on it, identified only by study #. The study team 363 member will be able to access this data and transfer it to the study-wide database 364 on the Y drive. 3654. The study-wide shared electronic database for the entry of day 3 and 10 responses 366 will be kept in the sinusitis study folder on the AMC Med-Ped Y drive, with 367 access limited to members of the study team only, and will identify participants 368 by study # only i.e. will contain no personal identifying information. 369 5. The material in the participant's study file will contain no information that is at all 370 likely to be embarrassing or compromising to the patient. 3716. The study team members are clinicians (physicians, office nurses, the pharmacy 372 professor (GG), and pharmacy students) who are part of the practice and already 373 have routine access to the patients' full medical records. The students from the 374 Albany College of Pharmacy and Health Sciences have full access to patient 375 records during their blocks in the office and, under the supervision of the 376 pharmacy professor, regularly review and counsel patients about their 377 medications. The medical students will not have access to the patient registry or 378 the study files, although they will of course know the names of the participants 379 whom they contact. 380 7. Study data will ultimately be entered into an Excel database. Individual 381 participants will be identified by study #, not by name; data will include sex and 382 age (but not date of birth). The database will be kept in the sinusitis study folder 383 of the AMC Y drive, with access limited to study team members. 384 8. When the trial is complete, the data analyzed, and the report accepted for 385 publication, we plan to notify participants of the study results and of the dosage 386 they received and then to destroy the patient registry. We will not destroy the files 387and